What is the recommended treatment for a patient with pertussis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Pertussis

Azithromycin is the first-line antibiotic for treating pertussis across all age groups, with a 5-day regimen that is equally effective as erythromycin but better tolerated. 1

First-Line Antibiotic Treatment

Azithromycin Dosing by Age

Infants <1 month:

  • Azithromycin is the preferred agent due to significantly lower risk of infantile hypertrophic pyloric stenosis (IHPS) compared to erythromycin 1
  • Dose: 10 mg/kg/day for 5 days 1
  • Note: Despite lack of FDA licensure in this age group, CDC explicitly recommends azithromycin because the risk of severe pertussis outweighs potential medication risks 1

Infants 1-5 months:

  • Azithromycin or clarithromycin are first-line options 1
  • Azithromycin dose: 10 mg/kg/day for 5 days 1
  • Clarithromycin dose: 7.5 mg/kg twice daily for 7 days 1

Children ≥6 months and adolescents:

  • Azithromycin: 10 mg/kg (maximum 500 mg) on day 1, then 5 mg/kg/day (maximum 250 mg) on days 2-5 1

Adults:

  • Azithromycin: 500 mg on day 1, then 250 mg daily on days 2-5 1

Alternative Agents

Clarithromycin:

  • Adults: 500 mg twice daily for 7 days 2
  • Children: 7.5 mg/kg (maximum 500 mg) twice daily for 7 days 1, 3
  • Equally effective as erythromycin with better tolerability 3

Trimethoprim-sulfamethoxazole (TMP-SMZ):

  • Reserved for patients >2 months with macrolide contraindications or hypersensitivity 1

Erythromycin (avoid if possible):

  • Should be avoided in infants <6 months due to strong association with IHPS 1
  • If absolutely necessary: 40-50 mg/kg/day in children or 1-2 g/day in adults for 14 days 1, 4
  • FDA-approved for pertussis and effective at eliminating organism from nasopharynx 4

Timing of Treatment and Expected Outcomes

Early treatment (catarrhal phase, first 1-2 weeks):

  • Rapidly clears B. pertussis from nasopharynx 1
  • Decreases coughing paroxysms and reduces complications 1
  • Most effective period for clinical benefit 1

Late treatment (paroxysmal phase, >3 weeks):

  • Limited clinical benefit for symptom improvement 1
  • Still indicated to prevent transmission to others 1
  • Natural history: 80-90% of untreated patients spontaneously clear bacteria within 3-4 weeks 1

Critical principle: Start antibiotics immediately upon clinical suspicion without waiting for culture confirmation 1

Isolation Requirements

  • Isolate patient at home and away from work/school for 5 days after starting antibiotics 1
  • Pertussis is highly contagious with secondary attack rate exceeding 80% among susceptible persons 1

Post-Exposure Prophylaxis (PEP)

Who should receive PEP:

  • All household contacts (strongly recommended) 2
  • Infants <12 months, especially <4 months 2
  • Pregnant women in third trimester 2
  • Healthcare workers with known exposure 1

PEP regimens:

  • Use the same antibiotics and dosing as for treatment 1, 2
  • Must be administered within 21 days of exposure to be effective 2
  • Azithromycin is preferred agent 2

Important Drug Interactions and Precautions

Azithromycin:

  • Do NOT take with aluminum- or magnesium-containing antacids (reduces absorption) 1
  • Does NOT inhibit cytochrome P450 enzymes (unlike erythromycin and clarithromycin) 1
  • Obtain baseline ECG in patients taking citalopram to exclude QTc prolongation before initiating 1
  • Use with caution in patients with impaired hepatic function 1

Erythromycin and clarithromycin:

  • Inhibit cytochrome P450 enzymes and can interact with digoxin, triazolam, ergot alkaloids 1
  • Contraindicated in patients with macrolide hypersensitivity 1

Common Pitfalls to Avoid

  1. Do not delay treatment waiting for culture confirmation - start immediately on clinical suspicion 1
  2. Do not use erythromycin in infants <6 months - azithromycin is safer 1
  3. Do not prescribe β-agonists, antihistamines, corticosteroids, or pertussis immunoglobulin - these have no proven benefit for controlling coughing paroxysms 1
  4. Do not forget to treat household contacts - prophylaxis is critical to prevent transmission 2
  5. Remember that antibiotic resistance to erythromycin is rare (<1%) 1

Vaccination Considerations

  • Verify and update vaccination status of patient and all household contacts 1
  • Vaccine immunity wanes after 5-10 years, making previously vaccinated individuals susceptible 1
  • Pregnant women should receive Tdap between 27-36 weeks' gestation with each pregnancy 1

References

Guideline

Treatment of Pertussis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Post-Exposure Prophylaxis for Pertussis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.